Potential for Fundamental Change in the Treatment of Brain Cancer
-
Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer
-
Based on recent international research showing key role of the brain chemical, glutamate, in driving aggressive growth of GBM
-
Noxopharm owns what it believes to be world-leading technology in glutamate-inhibition
-
Major opportunity to slow GBM growth and help preserve normal brain function
Sydney, 18 October 2019: Noxopharm (ASX: NOX) announces that it will apply its glutamate- inhibition technology to the treatment of glioblastoma multiforme (GBM).
GBM remains a poorly managed cancer, with surgery, radiotherapy and the chemotherapy drug, temozolomide, the current standard of care, offering median survival of only 12-15 months.
For further information please download the attached PDF:
